Top

Published in:

01-06-2011 | Original Article

Growth of kidney-transplanted pediatric patients treated with sirolimus

Authors: David González, Clotilde D. García, Marta Azócar, Simon Waller, Angel Alonso, Gema Ariceta, Natalia Mejía, Fernando Santos

Published in: Pediatric Nephrology | Issue 6/2011

Abstract

Experimental findings indicate that sirolimus (SRL) inhibits longitudinal growth by mechanisms potentially related to its inhibitory effects on both cell proliferation and expression of vascular endothelial growth factor (VEGF). The aim of this study was to investigate the growth pattern of kidney-transplanted children treated with SRL in a multicenter observational clinical study. Height, change in height SD (Δ height) and growth velocity of pediatric patients with renal transplant were calculated at 0, 6, 12, and 24 months after starting SRL. Controls of kidney-transplanted children not treated with SRL were matched by age, gender, renal function, and dose of corticosteroids. Sixty-eight children (34 SRL, 34 controls) were enrolled in the study. Nephrotoxicity was the most frequent indication to start therapy with SRL. SRL exerted an adverse effect on growth as demonstrated by significantly lower (p < 0.05) growth velocity (cm/year) and smaller change in height SD in the SRL group after 6 (4.08 vs. 6.56 and –0.05 vs. 0.14), 12 (4.44 vs. 6.11 and –0.03 vs. 0.28) and 24 (4.53 vs. 6.03 and –0.04 vs. 0.53) months of treatment. This study suggests that SRL therapy may interfere with growth of kidney-transplanted children. This undesirable effect needs to be taken into account when considering a switch to SRL and confirmed in further prospective trials including larger number of patients.

Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35:7S–14SCrossRef

Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926–1945CrossRef

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRef

Ibáñez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF (2007) Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 11:777–780CrossRef

Höcker B, Feneberg R, Köpf S, Weber LT, Waldherr R, Wühl E, Tönshoff B (2006) SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 10:593–601CrossRef

Ibáñez JP, Monteverde ML, Goldberg J, Diaz MA, Turconi A (2005) Sirolimus in pediatric renal transplantation. Transplant Proc 37:682–684CrossRef

Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Häyry P, Neylan JF (2004) Sirolimus-based therapy following early Cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4:953–961CrossRef

Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C (2006) Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 10:565–569CrossRef

Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18:446–449CrossRef

10.

Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323CrossRef

11.

Sindhi R (2003) Sirolimus in pediatric transplant recipients. Transplant Proc 35:113S–114SCrossRef

12.

Alvarez-García O, García-López E, Loredo V, Gil-Peña H, Rodríguez-Suárez J, Ordóñez FA, Carbajo-Pérez E, Santos F (2010) Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 78:561–568CrossRef

13.

Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez FA, Santos F (2007) Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 22:954–961CrossRef

14.

Sanchez CP, He YZ (2009) Bone growth during rapamycin therapy in young rats. BMC Pediatr 9:3CrossRef

15.

Rangel GA, Ariceta G (2009) Growth failure associated with sirolimus: case report. Pediatr Nephrol 24:2047–2050CrossRef

16.

Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Amst 34:571–590CrossRef

17.

Tanner JM, Marshall WA, Healy MJ, Goldstein H (1983) Assessment of skeletal maturity and prediction of adult height (tw2 method). 2nd edn. Academic Press, New York

18.

Fine RN (2010) Etiology and treatment of growth retardation in children with chronic kidney disease and end-stage renal disease: a historical perspective. Pediatr Nephrol 25:725–732CrossRef

19.

Nissel R, Brázda I, Feneberg R, Wigger M, Greiner C, Querfeld U, Haffner D (2004) Effect of renal transplantation in childhood on longitudinal growth and adult height. Kidney Int 66:792–800CrossRef

20.

Grenda R, Watson A, Trompeter R, Tönshoff B, Jaray J, Fitzpatrick M, Murer L, Vondrak K, Maxwell H, van Damme-Lombaerts R, Loirat C, Mor E, Cochat P, Milford DV, Brown M, Webb NJ (2010) A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant 10:828–836CrossRef

21.

Ferraris JR, Pasqualini T, Alonso G, Legal S, Sorroche P, Galich A, Coccia P, Ghezzi L, Ferraris V, Karabatas L, Guida C, Jasper H (2010) A study on strategies for improving growth and body composition after renal transplantation. Pediatr Nephrol 25:753–762CrossRef

22.

Li L, Chang A, Naesens M, Kambham N, Waskerwitz J, Martin J, Wong C, Alexander S, Grimm P, Concepcion W, Salvatierra O, Sarwal MM (2009) Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patients benefits. Am J Transplant 9:1362–1372CrossRef

23.

Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr (2003) Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 76:1331–1339CrossRef

24.

Grenda R (2010) Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. Pediatr Nephrol 25:747–752CrossRef

25.

Tejani A, Fine R, Alexander S, Harmon W, Stablein D (1993) Factors predictive of sustained growth in children after renal transplantation. J Pediatr 122:397–402CrossRef

26.

Harambat J, Cochat P (2009) Growth after renal transplantation. Pediatr Nephrol 24:1297–1306CrossRef

27.

North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2008 annual report. Available at: https://doi.org/web.emmes. com/study/ped/annlrept/annlrept.html. Accessed 8 Oct 2009.

28.

Alvarez-Garcia O, Garcia-Lopez E, Loredo V, Gil-Peña H, Rodriguez J, Ordoñez FA, Santos F (2010) Growth hormone (GH) administration improves longitudinal growth in rats with growth retardation induced by rapamycin. Pediatr Nephrol 25:31A

29.

Warshaw BL, Hymes LC (2010) Linear growth in pediatric renal transplant recipients is similar with sirolimus vs. calcineurin inhibitors. Presented at the American Transplant Congress, San Diego (CA) 2010 (abstract).

Title: Growth of kidney-transplanted pediatric patients treated with sirolimus
Authors: David González
Clotilde D. García
Marta Azócar
Simon Waller
Angel Alonso
Gema Ariceta
Natalia Mejía
Fernando Santos
Publication date: 01-06-2011
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 6/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-011-1811-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Growth of kidney-transplanted pediatric patients treated with sirolimus

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients

Nutcracker syndrome manifesting with severe proteinuria: a challenging scenario in a single-kidney patient

Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?

Hypochloremic metabolic alkalosis and failure to thrive: question

In memoriam: Professor Niilo Oskar Birger Hallman, July 15, 1916 – January 13, 2011

Orange-colored diapers in infants from families with gout